| OTHER BALANCE SHEET COMPONENTS |
NOTE 5 – OTHER BALANCE SHEET COMPONENTS Prepaid expenses and other current assets consisted of the following: | | | June 30,
2026 | | | December 31,
2025 | | | Prepaid insurance and other expenses | | $ | 2,385,781 | | | $ | 2,123,379 | | | Prepaid FDA user fees | | | 663,320 | | | | 994,979 | | | Prepaid legal expenses | | | 37,708 | | | | 1,465 | | | Deferred ATM offering costs | | | 223,096 | | | | 223,096 | | | Manufacturing deposit | | | 1,130,400 | | | | - | | | Others | | | 173,917 | | | | 202,532 | | | Prepaid expenses and other current assets | | $ | 4,614,222 | | | $ | 3,545,451 | | The manufacturing deposit relates to production of raw materials for the end of the 2026 fiscal year. Accounts payable and accrued expenses consisted of the following: | | | June 30,
2026 | | | December 31,
2025 | | | Accounts payable | | $ | 1,188,007 | | | $ | 3,067,616 | | | Accrued gross-to-net discounts | | | 1,467,440 | | | | 993,413 | | | Accrued inventory costs | | | 698,364 | | | | 450,321 | | | Accrued clinical research costs | | | 327,118 | | | | - | | | Accrued payroll and bonuses | | | 2,000,100 | | | | 2,872,403 | | | Other accrued liabilities | | | 556,957 | | | | 1,593,151 | | | Accounts payable and accrued liabilities | | $ | 6,237,986 | | | $ | 8,976,904 | |
|